Within the body's quiet machinery for keeping blood flowing, a clot must eventually be undone as well as formed, and the enzyme plasmin is the one that patiently dissolves it. Researchers at the University of Koblenz have now found that heme, the iron-bearing core of hemoglobin released when red blood cells break down, clings to plasmin with unusual strength and dampens its work. The finding offers a possible thread connecting a familiar molecular fact to the elevated clotting risk some people with hemolytic disorders carry, though whether that thread runs through living patients remains an op
Heme, a Hemoglobin Component, Shown to Inhibit the Enzyme That Helps Dissolve Blood Clots
A clot is only half the story.
Mark
So what exactly did the Koblenz team find?
Mimi
That plasmin, the enzyme that dissolves clots, grabs onto heme with high affinity. Once heme is bound, plasmin is much worse at breaking down fibrin.
Mark
And where does heme come from in the body?
Mimi
From hemoglobin. When red blood cells are destroyed faster than normal, in hemolytic diseases, labile heme can be released into the blood.
Luke
Before we get carried away, what's actually shown here?
Mimi
Binding and inhibition of plasmin's clot-breaking activity, and the inhibition scaled with heme concentration. It showed up at levels that can occur in pathologically increased red cell destruction.
Luke
But that doesn't prove it causes thrombosis in patients.
Mimi
Correct. The source says further research is needed to determine whether, and how much, this interaction matters in the disease itself.
Mark
What about the binding sites?
Mimi
Six potential sites were identified from peptides and simulations, with three on the surface looking most promising. Potential is the key word.
Luke
So the sites are predictions, not confirmed structures.
Mimi
As described, yes. The reporting doesn't say they've been pinned down further.
Il Polso
- A clot that stops bleeding must later be dissolved, and any delay in that clearing can leave vessels dangerously obstructed.
- In hemolytic disorders, red blood cells are destroyed faster than normal, flooding the bloodstream with heme that can interfere with other proteins.
- Koblenz researchers found heme binds plasmin rapidly and tightly, identifying six possible binding sites, three of them on the enzyme's surface.
- Even at heme levels seen in pathological hemolysis, clot-breaking activity was significantly suppressed, and the suppression grew with concentration.
- The team has framed this as a molecular building block, not a proven cause, and the open task now is confirming whether it shapes thrombosis risk in patients.
Within the body's quiet machinery for keeping blood flowing, a clot must eventually be undone as well as formed, and the enzyme plasmin is the one that patiently dissolves it. Researchers at the University of Koblenz have now found that heme, the iron-bearing core of hemoglobin released when red blood cells break down, clings to plasmin with unusual strength and dampens its work. The finding offers a possible thread connecting a familiar molecular fact to the elevated clotting risk some people with hemolytic disorders carry, though whether that thread runs through living patients remains an open question.
At the University of Koblenz, a team of four women led by Prof. Dr. Marie-T. Hopp has been asking an unglamorous but vital question: what happens after a clot does its job? Clots stop bleeding, but they must be removed, or they can block vessels for good. That removal, called fibrinolysis, depends on plasmin, which chews through the fibrin network that holds a clot together. Their findings, published in the International Journal of Biological Macromolecules, begin with a detail about hemolysis, the accelerated destruction of red blood cells seen in certain diseases. Those disorders release heme into the blood, and patients with some of them face higher thrombosis risk.
Hopp's group showed for the first time that plasmin binds heme with high affinity, and that it can take up several heme molecules very quickly. Using peptide analysis and computer simulations, they mapped six possible binding sites, three of them on the enzyme's surface. When heme was bound, plasmin's ability to dissolve clots dropped significantly, and the effect scaled with how much heme was present. Crucially, the suppression appeared at concentrations similar to those produced during pathological red cell destruction, suggesting the effect is not merely a laboratory curiosity.
The researchers are careful about what they have shown. Reduced clot clearing could contribute to the thrombosis risk in some hemolytic disorders, but they do not claim it does. Whether this interaction truly matters in patients, and how much, is the next chapter.
At the University of Koblenz, a team of four female researchers led by Prof. Dr. Marie-T. Hopp has found that heme, the iron-containing part of hemoglobin, attaches tightly to plasmin, the enzyme the body uses to dissolve blood clots. Their results appear in the International Journal of Biological Macromolecules.
The work starts from a simple observation: a clot is only half the story. Clots stop bleeding, but they must later be removed so they don't permanently block vessels. That removal is called fibrinolysis. In it, plasmin breaks down fibrin, the protein network that holds a clot together, and the clot dissolves.
The second piece of context is hemolysis, in which red blood cells are destroyed at an increased rate. In certain diseases this releases labile heme into the blood. Heme can interact with other proteins and change how they work. People with some hemolytic disorders face a higher risk of thrombosis, and the Koblenz group asked whether heme might be interfering with the clot-clearing machinery.
Hopp, who heads the Bioorganic Chemistry research group at Koblenz, said the team showed for the first time that plasmin binds heme with high affinity. They then tested what that strong interaction does to fibrinolysis. In her words, the findings offer a new molecular insight into why people with certain hemolytic disorders have a greater thrombosis risk.
Using biochemical and biophysical methods, the researchers found that plasmin can bind several heme molecules, and does so very rapidly. They then analyzed short peptides derived from plasmin and added computer simulations. This identified six potential heme-binding sites on the enzyme. Three of them, located on its surface, looked especially promising.
The key result concerned function. Bound heme significantly inhibited plasmin's ability to break down clots, and the degree of inhibition depended on how much heme was present. The effect appeared at heme concentrations like those that can occur when red blood cells are destroyed at pathologically high rates, which suggests the finding is not limited to extreme laboratory conditions.
The authors frame the work as a possible building block. Reduced fibrinolysis could contribute to the higher thrombosis risk seen in some hemolytic disorders. They stop short of claiming it does. Further research is needed to establish whether the heme-plasmin interaction actually plays a role in patients, and how large that role might be.
Citazioni salienti
The team showed for the first time that plasmin binds heme with high affinity, offering a new molecular insight into why some people with hemolytic disorders face higher thrombosis risk.— Prof. Dr. Marie-T. Hopp, University of Koblenz
Vuoi la storia completa?
Leggi l'originale su Medical Xpress ↗
Education